Navigation Links
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Date:2/26/2008

to the placebo group (28%; p=0.0276). Overall survival improvement trends were consistently observed across subsets of patients grouped by major prognostic factors, including disease stage, performance status, and line of therapy. Positive trends were also observed on the secondary endpoints including progression-free survival (PFS) and disease control rate.

In addition to the efficacy improvements, oral talactoferrin was well tolerated in this group of patients with previously treated NSCLC. Adverse events (AEs) were generally mild, and no drug-related serious AEs were reported. There were 26% fewer AEs and 48% fewer Grade 3/4/5 AEs in the talactoferrin group relative to the placebo group (p=0.0037 and p=0.0024, respectively).

"These exciting data hold promise for the historic battle being conducted to find effective treatments for the most lethal forms of cancer," said Dr. Peter Traber, President of Baylor College of Medicine, where talactoferrin was first produced in the laboratory. "It is our sincere hope that the Phase 3 trials of talactoferrin will be successful and this drug can eventually be used globally."

About the Phase 3 NSCLC Monotherapy Study

Building on the results of the two positive Phase 2 studies, preparations are underway for Phase 3 trials with talactoferrin in two NSCLC indications: (i) first-line in combination with chemotherapy, and (ii) monotherapy in patients who have failed two or more previous therapies.

The pivotal Phase 3, multinational, randomized, double-blind, placebo- controlled monotherapy study will enroll 720 patients with Stage IIIB or IV NSCLC who have failed two or more previous therapies. Patients will receive standard supportive care and be randomly assigned (2:1) to receive single- agent treatment with either oral talactoferrin or placebo until disease progression. Overall survival will be the primary endpoint for approval. Secondary endpoints include adverse event reductions, progression
'/>"/>

SOURCE Agennix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
8. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... YORK , August 21, 2014 ... Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license ... software for plant breeders and researchers, today is ... a joint venture with Seach Ltd, a leading ... formed to research and develop new breeds of ...
(Date:8/21/2014)... 2014  ACI Clinical ( www.aciclinical.com ) announces ... Committees. Using this solution, trial sponsors ... standard costs and receive the same expertise that ... services. Leveraging a decade of DMC ... development, statistical programming and meeting facilitation), ACI analyzed ...
(Date:8/21/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based dental, animal health and medical practitioners, announced today that ... , September 4, 2014 – Baird 2014 Healthcare ... p.m. ET , September 8, 2014 – ... , NY at 1:25 p.m. ET Henry ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Henry Schein To Present At Two Investor Conferences In September 2
... (Nasdaq: DNDN ) today announced that the ... convertible senior notes due January 15, 2016 (the "Notes") ... to purchase an additional $80 million aggregate principal amount ... exercise of the overallotment option, resulted in net proceeds ...
... Hospira, Inc. (NYSE: HSP ), the ... Food and Drug Administration (FDA) approval of Topotecan Injection, ... in the United States. The medication is a generic ... more than $140 million. Hospira,s topotecan is indicated for ...
Cached Medicine Technology:Dendreon Announces Exercise and Closing of Overallotment Option 2Hospira Announces FDA Approval of Topotecan Injection 2
(Date:8/21/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 ... at USD 236.1 million in 2011 and is estimated ... 2018 at a CAGR of 6.3% from 2012 to ... http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth in ...
(Date:8/21/2014)... 21, 2014 It's a terrible thing when ... to a serious substance abuse issue. When that happens to ... action is getting reliable help from the qualified substance abuse ... facility isn’t always easy for those young adults living in ... significant addiction issue. , Thankfully there is a new ...
(Date:8/21/2014)... The worlds of personal care and yoga are ... grab free products. BaliniSports will be shipping ... with all qualifying purchases for a limited time. “The ... apparel is simply perfect,” said Ada Hung, founder and ... brands is intended to give people in the yoga ...
(Date:8/21/2014)... Rockville, Maryland (PRWEB) August 21, 2014 ... developed with guidance from Lockton Companies and builds ... the industry’s only cellular glucometer, combined with Accountable ... and robust data analytic capabilities and adds a ... provider care, including eye exams, provider visits, HbA1c ...
(Date:8/21/2014)... Tibet has long been a desired ... kingdom. Prayers flags whip in the wind against ... rumble of chanting monks fill the otherwise silent temples. ... access to Tibet is challenging due to high elevation ... prove to be daunting for even the most experienced ...
Breaking Medicine News(10 mins):Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay News) -- ... summer months, new research shows. In a study using ... from Brigham and Women,s Hospital in Boston found that new ... spring and summer compared to colder times of the year. ...
... women during visits to family planning clinics whether their ... a type of intimate-partner violence called reproductive coercion ... continue to experience such pressures, according to a new ... School of Medicine. Young women who recently experienced ...
... A new study from Hasbro Children,s Hospital finds visits ... team sports have increased dramatically over a 10-year period, ... football. The number of sports-related concussions is highest in ... is significant and rising. The study is published in ...
... Alan Mozes HealthDay Reporter , SUNDAY, Aug. ... low-dose omega-3 fatty acid supplements don,t appear to gain ... research cautions. In fact, neither low doses of ... found in fish oil, nor of alpha-linolenic acid (ALA), ...
... Dr. Hernn Makse, professor of physics at The City College ... way that information and infectious diseases proliferate across complex networks. ... contrary to conventional wisdom, persons with the most connections are ... where someone is located in a network," said Professor Makse ...
... Austin,s new Health Information Technology program has received $2.7 ... and Education for Health Information Technology (PURE HIT) consortium ... of Health and Human Services Office of the National ... graduated its first class of 54 students this summer. ...
Cached Medicine News:Health News:Multiple Sclerosis Changes With the Seasons 2Health News:Multiple Sclerosis Changes With the Seasons 3Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 2Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 3Health News:Concussions in young athletes on the rise 2Health News:Concussions in young athletes on the rise 3Health News:Low-Dose Omega-3 Fatty Acids Don't Protect Heart Patients 2Health News:Low-Dose Omega-3 Fatty Acids Don't Protect Heart Patients 3Health News:Location determines social network influence, CCNY-led team finds 2Health News:Location determines social network influence, CCNY-led team finds 3Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 2Health News:Health IT program at the University of Texas at Austin receives $2.7 million in federal funding 3
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation. Two 25G ...
Medicine Products: